Stimwave gets FDA nod for StimQ neuromodulation device

Medical device company Stimwave Technologies has received U.S. Food and Drug Administration (FDA) for StimQ, a wireless MR-conditional neuromodulation stimulator device for treating chronic peripheral nerve pain.

The system pinpoints stimulation directly to the affected peripheral nerves using a multielectrode programmable device, according to the firm. It also allows patients to receive full-body MRI exams without having to remove implants, Stimwave said.